FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Described is a group of inventions comprising a monoclonal antibody or antigen-binding fragment thereof which binds to a human receptor-type protein tyrosine phosphatase σ (PTPRS) on a plasmacytoid dendrite cell (embodiments), hybridoma for producing said antibody, a method of producing a cell which produces an antibody, a method for producing an antibody recognizing human PTPRS, use of an animal cell which preserves the ability to express an endogenous polynucleotide which codes an amino acid sequence comprising an extracellular domain of human PTPRS, or a fraction of membranes of said cell for producing a monoclonal antibody, method of detecting a plasmacytoid dendrite cell, use of an antibody or a fragment thereof for detecting a plasmacytoid dendritic cell, method of inhibiting plasmacytoid dendritic cell activity ex vivo, use of an antibody or its fragment for treating a disease associated with pDC and for treating an autoimmune disease associated with IFNalpha.
EFFECT: invention extends the range of antibodies binding to human PTPRS.
16 cl, 18 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| ILT7 BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2756109C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
